Podcast Episodes
Back to Search“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika…
1 year, 7 months ago
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says
Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhati…
1 year, 7 months ago
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue”
Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a…
1 year, 8 months ago
FDA Approvals in Relapsed/Refractory CLL Set up ”Difficult Choice”
When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have …
1 year, 8 months ago
Oncologists Struggling With Cancer Deaths Among Millennial Patients
Oncologists are struggling with the rising cancer mortality rate among millennial patients. "I think treating people our own age is definitely a trig…
1 year, 8 months ago
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree
Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical onco…
1 year, 8 months ago
What Were the Biggest Data at ASCO 2024 in Kidney Cancer?
The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, …
1 year, 8 months ago
What New “Elephant in the Room” Means for Bladder Cancer Care
Enfortumab vedotin plus pembrolizumab (EV/pembro) has “become the elephant in the room” when it comes to bladder cancer care, says Jonathan E. Rosenb…
1 year, 8 months ago
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice
Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, …1 year, 9 months ago
”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care
From ASCO 2024.
When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S…
1 year, 9 months ago